Vol 2 (December 25, 2024): AME Clinical Trials Review

Cleaning the scope: have randomized clinical trials clarified the benefits of minimally invasive thoracic surgery for non-small cell lung cancer?—a narrative review

Less radiation, same bang, fewer bucks?

Neoadjuvant FOLFIRINOX in resectable pancreatic cancer: impact of the NORPACT-1 trial

Need of the hour—advancements in treatment of pancreatic cancer

Combining [¹⁷⁷Lu]Lu-PSMA-617 and enzalutamide in metastatic castration-resistant prostate cancer: promising but with caveats for now

Tislelizumab in hepatocellular carcinoma: a duet or a solo performance?

To fast or not to fast—that is the question?

The COMBAT trial: use of bipolar androgen therapy to enhance immune checkpoint blockade in the management of metastatic castration-resistant prostate cancer

Novel agents in acute lymphoblastic leukemia: an expanding role for inotuzumab ozogamicin in patients with measurable residual disease

Optimizing antiplatelet therapy after coronary artery bypass graft: selection, dosing, and duration

Comparison of drug-eluting bead transcatheter arterial chemoembolization (TACE) versus conventional TACE for hepatocellular carcinoma with portal vein thrombus

FLAURA in the real world: osimertinib in potentially trial-eligible and ineligible patients with EGFR-mutated advanced non-small cell lung cancer

Antiplatelet therapy after coronary artery bypass surgery: the results from the randomized DACAB trial

What is the optimal therapeutic option for patients diagnosed with hormone receptor-positive, HER2-negative breast cancer in visceral crisis?—insights from the RIGHT CHOICE trial

Ficonalkib: a new contender in ALK-positive non-small cell lung cancer treatment

The significance of local intervention for oligometastatic esophageal squamous cell carcinoma

From lifelong therapy to intermittent treatment: the future of chronic myeloid leukemia management—commentary on interim results from DAstop2 trial

Drug-coated ballons finally land in the United States: an appraisal of the agent IDE randomized clinical trial

Review on LAURA: is it a game changer for unresectable stage III EGFR-mutated non-small-cell lung cancer?

Can PET-CT improve the staging and outcome of patients with muscle-invasive bladder cancer?

Can robot-assisted oesophagectomy really improve outcomes?